IACC Votes to Redirect Autism Research Funding Toward Environmental Factors Including Vaccines

The committee, restructured in January 2026 with appointees aligned to Health Secretary Robert F. Kennedy Jr., heard explicit statements naming vaccines as an autism cause without challenge during the meeting. Members then voted to approve the plan, which de-emphasizes the genetics-first model supported by twin studies and genome-wide association analyses showing heritability estimates of 60-90 percent. No primary endpoint data or new cohort evidence was presented to justify the pivot.

Large observational studies, including the 2002 Danish cohort of 537,303 children published in the New England Journal of Medicine, found no association between MMR vaccination and autism incidence. Subsequent meta-analyses in JAMA and The Lancet have replicated null results across millions of participants. The IACC action instead allocates resources to areas lacking comparable epidemiological support, echoing earlier retracted claims and risking diversion of NIH funds from mechanistic research.

This decision occurs amid documented measles outbreaks linked to vaccine hesitancy and coincides with broader federal policy changes at CDC and HHS. Historical patterns show that advisory bodies influenced by singular viewpoints have delayed evidence-based public health responses, as seen in prior vaccine policy disputes. Future funding cycles will test whether the new priorities produce testable hypotheses or merely restate associations already ruled out by rigorous designs.

Next steps include submission of the plan to Congress and NIH for implementation guidance, with the first grant cycles expected in fiscal year 2027. Independent replication studies using pre-registered protocols on environmental exposures will be required to assess any incremental contribution beyond genetic architecture.